{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T21:21:33Z","timestamp":1762377693301,"version":"3.38.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100011851","name":"Kom op tegen Kanker","doi-asserted-by":"crossref","award":["KOTK_UZA\/2020\/12604\/1"],"award-info":[{"award-number":["KOTK_UZA\/2020\/12604\/1"]}],"id":[{"id":"10.13039\/501100011851","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"crossref","award":["1803723N"],"award-info":[{"award-number":["1803723N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-92254-8","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T13:00:36Z","timestamp":1741266036000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cracking the code of a correlate of protection against SARS-CoV-2 breakthrough infection in cancer patients"],"prefix":"10.1038","volume":"15","author":[{"given":"Yana","family":"Debie","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Garcia-Fogeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lander","family":"Willem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ella","family":"Roelant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lise","family":"Verbruggen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greetje","family":"Vanhoutte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lieselot","family":"Croes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christof","family":"Vulsteke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wim","family":"Demey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Willem","family":"Lybaert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Hanssens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Bols","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Van ongeval","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ann","family":"De Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hilde","family":"Jansens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria E.","family":"Goossens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annelies","family":"Janssens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Prenen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00e9bastien","family":"Anguille","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter A.","family":"van Dam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niel","family":"Hens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Abrams","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timon","family":"Vandamme","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"key":"92254_CR1","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.3201\/eid2609.202095","volume":"26","author":"RB Martines","year":"2020","unstructured":"Martines, R. B. et al. Pathology and pathogenesis of SARS-CoV-2 associated with fatal coronavirus disease, United States. Emerg. Infect. Dis. 26, 2005\u20132015. https:\/\/doi.org\/10.3201\/eid2609.202095 (2020).","journal-title":"Emerg. Infect. Dis."},{"key":"92254_CR2","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1016\/j.it.2020.10.004","volume":"41","author":"AG Harrison","year":"2020","unstructured":"Harrison, A. G., Lin, T. & Wang, P. Mechanisms of SARS-CoV-2 transmission and pathogenesis. Trends Immunol. 41, 1100\u20131115. https:\/\/doi.org\/10.1016\/j.it.2020.10.004 (2020).","journal-title":"Trends Immunol."},{"key":"92254_CR3","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.26355\/eurrev_202004_20871","volume":"24","author":"C Chakraborty","year":"2020","unstructured":"Chakraborty, C., Sharma, A. R., Sharma, G., Bhattacharya, M. & Lee, S. S. SARS-CoV-2 causing pneumonia-associated respiratory disorder (COVID-19): Diagnostic and proposed therapeutic options. Eur. Rev. Med. Pharmacol. Sci. 24, 4016\u20134026. https:\/\/doi.org\/10.26355\/eurrev_202004_20871 (2020).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"92254_CR4","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.annonc.2021.12.006","volume":"33","author":"AL Schmidt","year":"2022","unstructured":"Schmidt, A. L. et al. COVID-19 vaccination and breakthrough infections in patients with cancer. Ann. Oncol. 33, 340\u2013346. https:\/\/doi.org\/10.1016\/j.annonc.2021.12.006 (2022).","journal-title":"Ann. Oncol."},{"key":"92254_CR5","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.cmi.2021.09.036","volume":"28","author":"S Galmiche","year":"2022","unstructured":"Galmiche, S. et al. Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: A systematic review. Clin. Microbiol. Infect. 28, 163\u2013177. https:\/\/doi.org\/10.1016\/j.cmi.2021.09.036 (2022).","journal-title":"Clin. Microbiol. Infect."},{"key":"92254_CR6","doi-asserted-by":"publisher","first-page":"107327482110443","DOI":"10.1177\/10732748211044361","volume":"28","author":"RH Patel","year":"2021","unstructured":"Patel, R. H., Vanaparthy, R. & Greene, J. N. COVID-19 in immunocompromised cancer patients: A case series and review of the literature. Cancer Control. 28, 10732748211044361. https:\/\/doi.org\/10.1177\/10732748211044361 (2021).","journal-title":"Cancer Control"},{"key":"92254_CR7","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.ejca.2021.02.024","volume":"148","author":"P van Dam","year":"2021","unstructured":"van Dam, P. et al. Immunoglobin g\/total antibody testing for SARS-CoV-2: A prospective cohort study of ambulatory patients and health care workers in two Belgian oncology units comparing three commercial tests. Eur. J. Cancer. 148, 328\u2013339. https:\/\/doi.org\/10.1016\/j.ejca.2021.02.024 (2021).","journal-title":"Eur. J. Cancer"},{"key":"92254_CR8","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/s41571-022-00610-8","volume":"19","author":"A Fendler","year":"2022","unstructured":"Fendler, A. et al. COVID-19 vaccines in patients with cancer: Immunogenicity, efficacy and safety. Nat. Rev. Clin. Oncol. 19, 385\u2013401. https:\/\/doi.org\/10.1038\/s41571-022-00610-8 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"92254_CR9","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/s1473-3099(22)00320-6","volume":"22","author":"OJ Watson","year":"2022","unstructured":"Watson, O. J. et al. Global impact of the first year of COVID-19 vaccination: A mathematical modelling study. Lancet Infect. Dis. 22, 1293\u20131302. https:\/\/doi.org\/10.1016\/s1473-3099(22)00320-6 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"92254_CR10","doi-asserted-by":"publisher","first-page":"100180","DOI":"10.1016\/j.metop.2022.100180","volume":"14","author":"E Amanatidou","year":"2022","unstructured":"Amanatidou, E. et al. Breakthrough infections after COVID-19 vaccination: Insights, perspectives and challenges. Metabolism Open. 14, 100180. https:\/\/doi.org\/10.1016\/j.metop.2022.100180 (2022).","journal-title":"Metabolism Open."},{"key":"92254_CR11","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1016\/j.cmi.2021.06.036","volume":"27","author":"T Brosh-Nissimov","year":"2021","unstructured":"Brosh-Nissimov, T. et al. BNT162b2 vaccine breakthrough: Clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel. Clin. Microbiol. Infect. 27, 1652\u20131657. https:\/\/doi.org\/10.1016\/j.cmi.2021.06.036 (2021).","journal-title":"Clin. Microbiol. Infect."},{"key":"92254_CR12","doi-asserted-by":"publisher","first-page":"100274","DOI":"10.1016\/j.esmoop.2021.100274","volume":"6","author":"M Peeters","year":"2021","unstructured":"Peeters, M. et al. Reduced humoral immune response after BNT162b2 coronavirus disease 2019 messenger RNA vaccination in cancer patients under antineoplastic treatment. ESMO Open. 6, 100274. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100274 (2021).","journal-title":"ESMO Open."},{"key":"92254_CR13","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1001\/jamaoncol.2022.6815","volume":"9","author":"IY Gong","year":"2023","unstructured":"Gong, I. Y. et al. Association of COVID-19 vaccination with breakthrough infections and complications in patients with Cancer. JAMA Oncol. 9, 386\u2013394. https:\/\/doi.org\/10.1001\/jamaoncol.2022.6815 (2023).","journal-title":"JAMA Oncol."},{"key":"92254_CR14","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/s1470-2045(22)00202-9","volume":"23","author":"LYW Lee","year":"2022","unstructured":"Lee, L. Y. W. et al. Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): A population-based test-negative case-control study. Lancet Oncol. 23, 748\u2013757. https:\/\/doi.org\/10.1016\/s1470-2045(22)00202-9 (2022).","journal-title":"Lancet Oncol."},{"key":"92254_CR15","doi-asserted-by":"publisher","first-page":"e2381","DOI":"10.1002\/rmv.2381","volume":"32","author":"LB Shrestha","year":"2022","unstructured":"Shrestha, L. B., Foster, C., Rawlinson, W., Tedla, N. & Bull, R. A. Evolution of the SARS-CoV-2 Omicron variants BA.1 to BA.5: Implications for immune escape and transmission. Rev. Med. Virol. 32, e2381. https:\/\/doi.org\/10.1002\/rmv.2381 (2022).","journal-title":"Rev. Med. Virol."},{"key":"92254_CR16","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/s41564-022-01143-7","volume":"7","author":"BJ Willett","year":"2022","unstructured":"Willett, B. J. et al. SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. Nat. Microbiol. 7, 1161\u20131179. https:\/\/doi.org\/10.1038\/s41564-022-01143-7 (2022).","journal-title":"Nat. Microbiol."},{"key":"92254_CR17","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.1016\/j.vaccine.2023.03.069","volume":"41","author":"T Braeye","year":"2023","unstructured":"Braeye, T. et al. Vaccine effectiveness against transmission of alpha, delta and Omicron SARS-COV-2-infection, Belgian contact tracing, 2021\u20132022. Vaccine 41, 3292\u20133300. https:\/\/doi.org\/10.1016\/j.vaccine.2023.03.069 (2023).","journal-title":"Vaccine"},{"key":"92254_CR18","doi-asserted-by":"publisher","first-page":"7437","DOI":"10.1038\/s41598-023-34035-9","volume":"13","author":"OM Esp\u00edndola","year":"2023","unstructured":"Esp\u00edndola, O. M. et al. Reduced ability to neutralize the Omicron variant among adults after infection and complete vaccination with BNT162b2, ChAdOx1, or coronavac and heterologous boosting. Sci. Rep. 13, 7437. https:\/\/doi.org\/10.1038\/s41598-023-34035-9 (2023).","journal-title":"Sci. Rep."},{"key":"92254_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12998\/wjcc.v10.i1.1","volume":"10","author":"SY Ren","year":"2022","unstructured":"Ren, S. Y., Wang, W. B., Gao, R. D. & Zhou, A. M. Omicron variant (B.1.1.529) of SARS-CoV-2: Mutation, infectivity, transmission, and vaccine resistance. World J. Clin. Cases. 10, 1\u201311. https:\/\/doi.org\/10.12998\/wjcc.v10.i1.1 (2022).","journal-title":"World J. Clin. Cases"},{"key":"92254_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27588","author":"Y Araf","year":"2022","unstructured":"Araf, Y. et al. Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines. J. Med. Virol. https:\/\/doi.org\/10.1002\/jmv.27588 (2022).","journal-title":"J. Med. Virol."},{"key":"92254_CR21","doi-asserted-by":"publisher","first-page":"100458","DOI":"10.1016\/j.esmoop.2022.100458","volume":"7","author":"A Lasagna","year":"2022","unstructured":"Lasagna, A. et al. Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: A prospective cohort study. ESMO Open. 7, 100458. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100458 (2022).","journal-title":"ESMO Open."},{"key":"92254_CR22","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1086\/589862","volume":"47","author":"SA Plotkin","year":"2008","unstructured":"Plotkin, S. A. Vaccines: Correlates of vaccine-induced immunity. Clin. Infect. Dis. Off. Publ.  Infect. Dis. Soc. Am. 47, 401\u2013409. https:\/\/doi.org\/10.1086\/589862 (2008).","journal-title":"Clin. Infect. Diseases: Official Publication Infect. Dis. Soc. Am."},{"key":"92254_CR23","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205\u20131211. https:\/\/doi.org\/10.1038\/s41591-021-01377-8 (2021).","journal-title":"Nat. Med."},{"key":"92254_CR24","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1093\/cid\/cis238","volume":"54","author":"SA Plotkin","year":"2012","unstructured":"Plotkin, S. A. & Gilbert, P. B. Nomenclature for immune correlates of protection after vaccination. Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am. 54, 1615\u20131617. https:\/\/doi.org\/10.1093\/cid\/cis238 (2012).","journal-title":"Clin. Infect. Diseases: Official Publication Infect. Dis. Soc. Am."},{"key":"92254_CR25","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/s41591-021-01432-4","volume":"27","author":"F Krammer","year":"2021","unstructured":"Krammer, F. A correlate of protection for SARS-CoV-2 vaccines is urgently needed. Nat. Med. 27, 1147\u20131148. https:\/\/doi.org\/10.1038\/s41591-021-01432-4 (2021).","journal-title":"Nat. Med."},{"key":"92254_CR26","doi-asserted-by":"publisher","unstructured":"Debie, Y., Vandamme, T., Goossens, M. E., van Dam, P. A. & Peeters, M. Antibody titers before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in Cancer patients. Eur. J. Cancer https:\/\/doi.org\/10.1016\/j.ejca.2021.12.025","DOI":"10.1016\/j.ejca.2021.12.025"},{"key":"92254_CR27","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1158\/1078-0432.Ccr-22-2185","volume":"29","author":"Y Debie","year":"2023","unstructured":"Debie, Y. et al. Humoral and cellular immune responses against SARS-CoV-2 after third dose BNT162b2 following Double-Dose vaccination with BNT162b2 versus ChAdOx1 in patients with Cancer. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res. 29, 635\u2013646. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-22-2185 (2023).","journal-title":"Clin. cancer Research: Official J. Am. Association Cancer Res."},{"key":"92254_CR28","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.ejca.2022.11.016","volume":"179","author":"Y Debie","year":"2023","unstructured":"Debie, Y., van Dam, P. A., Goossens, M. E., Peeters, M. & Vandamme, T. Boosting capacity of a fourth dose BNT162b2 in cancer patients. Eur. J. Cancer. 179, 121\u2013123. https:\/\/doi.org\/10.1016\/j.ejca.2022.11.016 (2023).","journal-title":"Eur. J. Cancer"},{"key":"92254_CR29","doi-asserted-by":"publisher","first-page":"115486","DOI":"10.1016\/j.diagmicrobio.2021.115486","volume":"101","author":"M Cuykx","year":"2021","unstructured":"Cuykx, M. et al. Serological response in health care workers after a single dose of SARS-CoV-2 vaccine using six automated SARS-CoV-2 antibody assays. Diagn. Microbiol. Infect. Dis. 101, 115486. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2021.115486 (2021).","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"92254_CR30","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1515\/cclm-2021-0214","volume":"59","author":"C Irsara","year":"2021","unstructured":"Irsara, C. et al. Clinical validation of the Siemens quantitative SARS-CoV-2 Spike IgG assay (sCOVG) reveals improved sensitivity and a good correlation with virus neutralization titers. Clin. Chem. Lab. Med. 59, 1453\u20131462. https:\/\/doi.org\/10.1515\/cclm-2021-0214 (2021).","journal-title":"Clin. Chem. Lab. Med."},{"key":"92254_CR31","unstructured":"Sciensano The COVID-19 Test Results data collection, (2022). https:\/\/docs.healthdata.be\/documentation\/covid-19-test-results\/covid-19-test-results-data-collection"},{"key":"92254_CR32","unstructured":"RCoreTeam. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing (2023). https:\/\/www.R-project.org\/"},{"key":"92254_CR33","unstructured":"WHO. The Pfizer BioNTech (BNT162b2) COVID-19 vaccine: What you need to know (2022). https:\/\/www.who.int\/news-room\/feature-stories\/detail\/who-can-take-the-pfizer-biontech-covid-19--vaccine-what-you-need-to-know"},{"key":"92254_CR34","unstructured":"WHO. The Moderna COVID-19 (mRNA-1273) vaccine: What you need to know (2022). https:\/\/www.who.int\/news-room\/feature-stories\/detail\/the-moderna-covid-19-mrna-1273-vaccine-what-you-need-to-know"},{"key":"92254_CR35","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1038\/s43018-021-00274-w","volume":"2","author":"A Fendler","year":"2021","unstructured":"Fendler, A. et al. Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: The CAPTURE study. Nat. Cancer. 2, 1321\u20131337. https:\/\/doi.org\/10.1038\/s43018-021-00274-w (2021).","journal-title":"Nat. cancer"},{"key":"92254_CR36","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1111\/irv.13030","volume":"16","author":"Y Chong","year":"2022","unstructured":"Chong, Y. et al. Pronounced antibody elevation after SARS-CoV-2 BNT162b2 mRNA booster vaccination in nursing home residents. Influenza Other Respir Viruses. 16, 1066\u20131071. https:\/\/doi.org\/10.1111\/irv.13030 (2022).","journal-title":"Influenza Other Respir Viruses"},{"key":"92254_CR37","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac301","author":"NE Aikawa","year":"2022","unstructured":"Aikawa, N. E. et al. Strong response after 4th dose of mRNA COVID-19 vaccine in autoimmune rheumatic diseases patients with poor response to inactivated vaccine. Rheumatol. (Oxf. Engl.). https:\/\/doi.org\/10.1093\/rheumatology\/keac301 (2022).","journal-title":"Rheumatol. (Oxford England)"},{"key":"92254_CR38","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ejca.2021.12.011","volume":"162","author":"J Barri\u00e8re","year":"2022","unstructured":"Barri\u00e8re, J. et al. Third dose of anti-SARS-CoV-2 vaccine for patients with cancer: Should humoral responses be monitored? A position Article. Eur. J. Cancer. 162, 182\u2013193. https:\/\/doi.org\/10.1016\/j.ejca.2021.12.011 (2022).","journal-title":"Eur. J. Cancer"},{"key":"92254_CR39","doi-asserted-by":"publisher","first-page":"e071502","DOI":"10.1136\/bmj-2022-071502","volume":"378","author":"R Grewal","year":"2022","unstructured":"Grewal, R. et al. Effectiveness of a fourth dose of covid-19 mRNA vaccine against the Omicron variant among long term care residents in Ontario, Canada: Test negative design study. BMJ (Clin. Res. Ed.). 378, e071502. https:\/\/doi.org\/10.1136\/bmj-2022-071502 (2022).","journal-title":"BMJ (Clinical Res. ed.)"},{"key":"92254_CR40","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1001\/jamaoncol.2021.2155","volume":"7","author":"A Massarweh","year":"2021","unstructured":"Massarweh, A. et al. Evaluation of seropositivity following BNT162b2 messenger RNA vaccination for SARS-CoV-2 in patients undergoing treatment for Cancer. JAMA Oncol. 7, 1133\u20131140. https:\/\/doi.org\/10.1001\/jamaoncol.2021.2155 (2021).","journal-title":"JAMA Oncol."},{"key":"92254_CR41","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1056\/NEJMc2108861","volume":"385","author":"N Kamar","year":"2021","unstructured":"Kamar, N. et al. Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients. N. Engl. J. Med. 385, 661\u2013662. https:\/\/doi.org\/10.1056\/NEJMc2108861 (2021).","journal-title":"N Engl. J. Med."},{"key":"92254_CR42","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.19885","author":"N Eliakim-Raz","year":"2021","unstructured":"Eliakim-Raz, N. et al. Antibody titers before and after a third dose of the SARS-CoV-2 BNT162b2 vaccine in adults aged\u2009\u2265\u200960 years. JAMA https:\/\/doi.org\/10.1001\/jama.2021.19885 (2021).","journal-title":"JAMA"},{"key":"92254_CR43","doi-asserted-by":"publisher","first-page":"e225","DOI":"10.1093\/oncolo\/oyad003","volume":"28","author":"I Cohen","year":"2023","unstructured":"Cohen, I., Campisi-Pfinto, S., Rozenberg, O., Colodner, R. & Bar-Sela, G. The humoral response of patients with Cancer to breakthrough COVID-19 infection or the fourth BNT162b2 vaccine dose. Oncologist 28, e225\u2013e227. https:\/\/doi.org\/10.1093\/oncolo\/oyad003 (2023).","journal-title":"Oncologist"},{"key":"92254_CR44","doi-asserted-by":"publisher","first-page":"e069761","DOI":"10.1136\/bmj-2021-069761","volume":"376","author":"AS Lauring","year":"2022","unstructured":"Lauring, A. S. et al. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from Omicron, delta, and alpha SARS-CoV-2 variants in the United States: Prospective observational study. BMJ (Clin. Res. Ed.). 376, e069761. https:\/\/doi.org\/10.1136\/bmj-2021-069761 (2022).","journal-title":"BMJ (Clinical Res. ed.)"},{"key":"92254_CR45","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1038\/s41408-022-00778-3","volume":"13","author":"JL Pi\u00f1ana","year":"2023","unstructured":"Pi\u00f1ana, J. L. et al. One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients. Blood Cancer J. 13, 8. https:\/\/doi.org\/10.1038\/s41408-022-00778-3 (2023).","journal-title":"Blood Cancer J."},{"key":"92254_CR46","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/s0140-6736(23)01180-7","volume":"402","author":"R Wijaya","year":"2023","unstructured":"Wijaya, R. et al. Predicting COVID-19 infection risk in people who are immunocompromised by antibody testing. Lancet 402, 99\u2013102. https:\/\/doi.org\/10.1016\/s0140-6736(23)01180-7 (2023).","journal-title":"Lancet"},{"key":"92254_CR47","doi-asserted-by":"publisher","first-page":"e612","DOI":"10.1016\/s2666-5247(23)00107-6","volume":"4","author":"L Seekircher","year":"2023","unstructured":"Seekircher, L. et al. Immune response after two doses of the BNT162b2 COVID-19 vaccine and risk of SARS-CoV-2 breakthrough infection in Tyrol, Austria: An open-label, observational phase 4 trial. Lancet Microbe. 4, e612\u2013e621. https:\/\/doi.org\/10.1016\/s2666-5247(23)00107-6 (2023).","journal-title":"Lancet Microbe"},{"key":"92254_CR48","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","volume":"27","author":"S Feng","year":"2021","unstructured":"Feng, S. et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat. Med. 27, 2032\u20132040. https:\/\/doi.org\/10.1038\/s41591-021-01540-1 (2021).","journal-title":"Nat. Med."},{"key":"92254_CR49","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1016\/j.vaccine.2021.05.063","volume":"39","author":"KA Earle","year":"2021","unstructured":"Earle, K. A. et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 39, 4423\u20134428. https:\/\/doi.org\/10.1016\/j.vaccine.2021.05.063 (2021).","journal-title":"Vaccine"},{"key":"92254_CR50","doi-asserted-by":"publisher","first-page":"ofac262","DOI":"10.1093\/ofid\/ofac262","volume":"9","author":"MH Kim","year":"2022","unstructured":"Kim, M. H. et al. Antibody level predicts the clinical course of breakthrough infection of COVID-19 caused by Delta and Omicron variants: A prospective cross-sectional study. Open. Forum Infect. Dis. 9, ofac262. https:\/\/doi.org\/10.1093\/ofid\/ofac262 (2022).","journal-title":"Open. Forum Infect. Dis."},{"key":"92254_CR51","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12929-022-00853-8","volume":"29","author":"WY Chi","year":"2022","unstructured":"Chi, W. Y. et al. COVID-19 vaccine update: Vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection. J. Biomed. Sci. 29, 82. https:\/\/doi.org\/10.1186\/s12929-022-00853-8 (2022).","journal-title":"J. Biomed. Sci."},{"key":"92254_CR52","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1056\/NEJMoa2109072","volume":"385","author":"M Bergwerk","year":"2021","unstructured":"Bergwerk, M. et al. Covid-19 breakthrough infections in vaccinated health care workers. N. Engl. J. Med. 385, 1474\u20131484. https:\/\/doi.org\/10.1056\/NEJMoa2109072 (2021).","journal-title":"N Engl. J. Med."},{"key":"92254_CR53","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.vaccine.2021.12.006","volume":"40","author":"D Goldblatt","year":"2022","unstructured":"Goldblatt, D. et al. Towards a population-based threshold of protection for COVID-19 vaccines. Vaccine 40, 306\u2013315. https:\/\/doi.org\/10.1016\/j.vaccine.2021.12.006 (2022).","journal-title":"Vaccine"},{"key":"92254_CR54","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1111\/joim.13776","volume":"295","author":"G Zhou","year":"2024","unstructured":"Zhou, G. et al. The dynamics of B-cell reconstitution post allogeneic hematopoietic stem cell transplantation: A real-world study. J. Intern. Med. 295, 634\u2013650. https:\/\/doi.org\/10.1111\/joim.13776 (2024).","journal-title":"J. Intern. Med."},{"key":"92254_CR55","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1182\/asheducation-2015.1.215","volume":"2015","author":"MR van den Brink","year":"2015","unstructured":"van den Brink, M. R., Velardi, E. & Perales, M. A. Immune reconstitution following stem cell transplantation. Hematol. Am. Soc. Hematol. Educ. Progr. 2015, 215\u2013219. https:\/\/doi.org\/10.1182\/asheducation-2015.1.215 (2015).","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program."},{"key":"92254_CR56","doi-asserted-by":"publisher","first-page":"2551","DOI":"10.1007\/s00210-023-02781-2","volume":"397","author":"A Sharma","year":"2024","unstructured":"Sharma, A., Jasrotia, S. & Kumar, A. Effects of chemotherapy on the immune system: implications for Cancer treatment and patient outcomes. Naunyn Schmiedebergs Arch. Pharmacol. 397, 2551\u20132566. https:\/\/doi.org\/10.1007\/s00210-023-02781-2 (2024).","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"92254_CR57","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nri2216","volume":"8","author":"L Zitvogel","year":"2008","unstructured":"Zitvogel, L., Apetoh, L., Ghiringhelli, F. & Kroemer, G. Immunological aspects of cancer chemotherapy. Nat. Rev. Immunol. 8, 59\u201373. https:\/\/doi.org\/10.1038\/nri2216 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"92254_CR58","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1111\/imr.13091","volume":"310","author":"D Goldblatt","year":"2022","unstructured":"Goldblatt, D., Alter, G., Crotty, S. & Plotkin, S. A. Correlates of protection against SARS-CoV-2 infection and COVID-19 disease. Immunol. Rev. 310, 6\u201326. https:\/\/doi.org\/10.1111\/imr.13091 (2022).","journal-title":"Immunol. Rev."},{"key":"92254_CR59","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s41232-022-00233-7","volume":"42","author":"Y Liu","year":"2022","unstructured":"Liu, Y. & Arase, H. Neutralizing and enhancing antibodies against SARS-CoV-2. Inflamm. Regen. 42, 58. https:\/\/doi.org\/10.1186\/s41232-022-00233-7 (2022).","journal-title":"Inflamm. Regen"},{"key":"92254_CR60","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41586-020-03041-6","volume":"590","author":"K McMahan","year":"2021","unstructured":"McMahan, K. et al. Correlates of protection against SARS-CoV-2 in rhesus macaques. Nature 590, 630\u2013634. https:\/\/doi.org\/10.1038\/s41586-020-03041-6 (2021).","journal-title":"Nature"},{"key":"92254_CR61","doi-asserted-by":"publisher","first-page":"837","DOI":"10.2307\/2531595","volume":"44","author":"ER DeLong","year":"1988","unstructured":"DeLong, E. R., DeLong, D. M. & Clarke-Pearson, D. L. Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach. Biometrics 44, 837\u2013845 (1988).","journal-title":"Biometrics"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92254-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92254-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92254-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T13:00:41Z","timestamp":1741266041000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-92254-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["92254"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-92254-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,6]]},"assertion":[{"value":"23 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"TV reports consultancy, advisory roles and honoraria from AstraZeneca outside the scope of presented work. The other authors report no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Ethics Committee Antwerp University Hospital (EC nos. 2021\u20130543 dd. 01\/02\/2021, 2021-0541 dd. 09\/08\/2021, 21\/12\/172 dd. 17\/05\/2021).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}},{"value":"Informed consent was obtained from all subjects involved in the studies.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"7858"}}